Other substances

Galidesivir

An adenosine analogue.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Galidesivir on PubChem

Structure image - Galidesivir

C1=C(C2=C(N1)C(=NC=N2)N)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase RdRpol Small molecule In silico	in silico	2.01	The triphosphate active metabolite was predicted to inhibit SARS-CoV-2 RNA-dependent RNA polymerase.	Mar/25/2021

AI-suggested references

Link	Publication date
Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19.	Sep/12/2020
In silico investigation of the interactions of certain drugs proposed for the treatment of Covid-19 with the paraoxonase-1.	Dec/13/2021
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.	Dec/16/2020
Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2.	Jul/19/2021
Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.	Nov/29/2021
Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an in silico perspective	Jun/30/2020
On a knife's edge of a COVID-19 pandemic: is containment still possible?	Mar/09/2020
In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.	Mar/25/2021
Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks	May/22/2020
SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective	May/06/2020
Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation	Mar/05/2021
Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic	Dec/04/2020
Activity of Galidesivir in a Hamster Model of SARS-CoV-2	Dec/24/2020
Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study	Mar/25/2020
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication	Jan/24/2021
Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.	Jul/07/2020
Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters.	Nov/11/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT03891420	A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19	Terminated	Phase 1	Apr/09/2020	Apr/30/2021
Alternative id - BCX4430-108\|272201300017C-18-0-1\|DMID18-0022 Interventions - Drug: Galidesivir\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Parana, Brazil\|Hospital Sao Vicente de Paulo-PPDS, Passo Fundo, Rio Grande Do Sul, Brazil\|Hospital Sao Lucas da Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil\|Foundation Regional Faculty of Medicine of São José do Rio Preto, São José Do Rio Preto, SP, Brazil\|Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo, SP, Brazil Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Double (Participant, Investigator)\|Primary Purpose: Treatment Enrollment - 24 Age - 18 Years and older (Adult, Older Adult) Outcome measures - number of subjects with treatment emergent adverse events and serious adverse events\|number of subjects with change in laboratory parameters\|exposure of galidesivir as measured by plasma concentrations\|yellow fever virus (YFV) titer (Group A)\|antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)\|changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)\|changes from baseline and time to improvement using NEWS in COVID-19 (Group B)\|mortality